Glycomet Trio 1 Tablet SR is a combination oral hypoglycemic agent formulated to manage type 2 diabetes mellitus effectively. It contains Glimepiride 1 mg, Metformin 500 mg, and Voglibose 0.2 mg, each contributing distinct mechanisms to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, facilitating better glucose uptake by tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, reducing postprandial hyperglycemia. The sustained-release formulation ensures gradual drug release, promoting consistent plasma concentrations and improving patient compliance. Glycomet Trio 1 Tablet SR is indicated for patients inadequately controlled by diet and exercise alone or those requiring combination therapy to achieve target glycemic levels. It is essential to monitor blood glucose regularly and adjust dosage based on therapeutic response and tolerability. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare allergic reactions. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.